10/12/2024

Amoxapine Tablets

Products Affected - Description

- Amoxapine oral tablet, Teva, 100 mg, bottle, 100 count, NDC 00591-5715-01
- Amoxapine oral tablet, Teva, 150 mg, bottle, 30 count, NDC 00591-5716-30
- Amoxapine oral tablet, Teva, 25 mg, bottle, 100 count, NDC 00591-5713-01

Reason for the Shortage

- Chartwell has amoxapine tablets available.
- Teva did not provide a reason for the shortage.

Available Products

- Amoxapine oral tablet, Chartwell, 100 mg, bottle, 90 count, NDC 62135-0702-90
- Amoxapine oral tablet, Chartwell, 150 mg, bottle, 30 count, NDC 62135-0703-30
- Amoxapine oral tablet, Chartwell, 25 mg, bottle, 90 count, NDC 62135-0700-90
- Amoxapine oral tablet, Chartwell, 50 mg, bottle, 90 count, NDC 62135-0701-90
- Amoxapine oral tablet, Teva, 50 mg, bottle, 100 count, NDC 00591-5714-01

Estimated Resupply Dates

- Teva has amoxapine 25 mg, 100 mg, and 150 mg tablets on back order and the company estimates a release date of mid-November 2024.

Updated

Updated October 12, 2024 by Elyse MacDonald, PharmD, MS, BCPS. Created August 20, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.